Efficacy of Retreatments With Intravitreal Bevacizumab

This study is currently recruiting participants.

Verified by Asociación para Evitar la Ceguera en México, November 2006

Sponsored by:	Asociación para Evitar la Ceguera en México
Information provided by:	Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:	NCT00406744

Purpose

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Condition	Intervention	Phase
Age Related Macular Degeneration Choroidal Neovascularization	Drug: Intravitreal injection of Bevacizumab	Phase III

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

Drug Information available for: Bevacizumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:

Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram

Estimated Enrollment:	20
Study Start Date:	May 2006
Estimated Study Completion Date:	November 2006

Eligibility

Ages Eligible for Study:	60 Years to 95 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

* Any visual acuity
- OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
- Active angiogram leakage

Exclusion Criteria:

* Basal Inflammatory disease
- Endoftalmitis history
- Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00406744

Contacts

Contact: Veronica A Kon-Jara, MD	525510841400 ext 1172	veronicakon@yahoo.com
Contact: Hugo Quiroz-Mercado, MD	525510841400 ext 1171	retinamex@yahoo.com

Locations

Mexico, DF
Asociacion para Evitar la Ceguera en Mexico	Recruiting
Mexico DF, DF, Mexico, 04030
Contact: Veronica Kon-Jara, MD 525510841400 ext 1171 veronicakon@yahoo.com
Principal Investigator: Veronica Kon-Jara, MD
Sub-Investigator: Mitzy Torres-Soriano, MD
Sub-Investigator: Jose Luis Diaz-Rubio, MD
Sub-Investigator: Myriam Hernandez, MD
Sub-Investigator: Hugo Quiroz-Mercado, MD

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Investigators

Principal Investigator:

Veronica Kon-Jara, MD

APEC

More Information

Study ID Numbers:	APEC-0012
Study First Received:	November 30, 2006
Last Updated:	November 30, 2006
ClinicalTrials.gov Identifier:	NCT00406744
Health Authority:	Mexico: National Institute of Public Health, Health Secretariat

Keywords provided by Asociación para Evitar la Ceguera en México:

neovascularization

Study placed in the following topic categories:

Metaplasia
Eye Diseases
Choroid Diseases
Retinal Degeneration
Macular Degeneration

Bevacizumab
Neovascularization, Pathologic
Retinal Diseases
Retinal degeneration
Choroidal Neovascularization

Additional relevant MeSH terms:

Uveal Diseases
Pathologic Processes
Antineoplastic Agents
Therapeutic Uses
Growth Substances

Physiological Effects of Drugs
Growth Inhibitors
Angiogenesis Modulating Agents
Angiogenesis Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009